{
    "Clinical Trial ID": "NCT01289353",
    "Intervention": [
        "INTERVENTION 1: ",
        "  ChemoRT",
        "  Concurrent Carboplatin and Radiotherapy",
        "  Carboplatin: IV, weekly for 6 weeks, AUC of 2.0",
        "  3D-RT or IMRT: From week 2 to week 4 in the 6-week Carboplatin treatment: Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Age older than 18",
        "  Pre- or post-menopausal women with Stage I and II breast cancer, triple negative tumors",
        "  Biopsy-proven invasive breast cancer, excised with negative margins of at least 1 mm",
        "  Status post segmental mastectomy, after sentinel node biopsy and/or axillary node dissection (Tumors < 5 mm in size do not require nodal assessment) or after mastectomy",
        "  No previous chemotherapy",
        "  Patient needs to be able to understand and demonstrate willingness to sign a written informed consent document",
        "Exclusion Criteria:",
        "  Previous radiation therapy to the ipsilateral breast",
        "  Active connective tissue disorders, such as lupus or scleroderma",
        "  Pregnant or lactating women"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Patients Who Developed Grade 2-3 Acute Radiation Dermatitis Within 60 Days Post-RT",
        "  [Not Specified]",
        "  Time frame: 60 days post-RT",
        "Results 1: ",
        "  Arm/Group Title: ChemoRT",
        "  Arm/Group Description: Concurrent Carboplatin and Radiotherapy",
        "  Carboplatin: IV, weekly for 6 weeks, AUC of 2.0",
        "  3D-RT or IMRT: From week 2 to week 4 in the 6-week Carboplatin treatment: Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy",
        "  Overall Number of Participants Analyzed: 90",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  8   8.9%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/90 (0.00%)"
    ]
}